Larger subcutaneous injections are becoming more prominent due to recent advances in formulation development and new therapeutic areas. Therefore, novel large volume autoinjectors need to be developed to fulfill this new demand. As the interplay of device and container is crucial for a safe and reliable drug administration, a co-development between container and device manufacturers is a meaningful way to understand and address all relevant stakeholder needs.

In this Pharmaversity® session experts from SCHOTT Pharma and Ypsomed will provide an insight into how pharmaceutical requirements, user needs, processability, and business requirements have guided the co-development of YpsoMate 5.5 autoinjector and syriQ BioPure® 5.5ml prefillable glass syringe.

Learn more about your ad choices. Visit megaphone.fm/adchoices